<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioAlps</title>
	<atom:link href="https://bioalps.org/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioalps.org/</link>
	<description>Your entry point to a wealth of contacts, know-how and knowledge, for both personal and institutional support: BioAlps, the life science cluster of Western Switzerland.</description>
	<lastBuildDate>Fri, 13 Nov 2026 16:46:31 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioalps.org/app/uploads/2022/11/cropped-favicon-32x32.png</url>
	<title>BioAlps</title>
	<link>https://bioalps.org/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Datarium at BioAlps Networking Day</title>
		<link>https://bioalps.org/datarium-at-bioalps-networking-day/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 16:00:09 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[data]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38340</guid>

					<description><![CDATA[<p><img width="768" height="477" src="https://bioalps.org/app/uploads/2026/11/Datarium-at-BND.png" class="attachment-large size-large wp-post-image" alt="Datarium at BND" style="float:left; margin:0 15px 15px 0;" decoding="async" fetchpriority="high" srcset="https://bioalps.org/app/uploads/2026/11/Datarium-at-BND.png 768w, https://bioalps.org/app/uploads/2026/11/Datarium-at-BND-300x186.png 300w" sizes="(max-width: 768px) 100vw, 768px" />Exploring the data of life during the BioAlps Networking Day with the Datarium exhibition created by the Swiss Institute of Bioinformatics. What if your future treatment were already written in your DNA? Did you know that a single cancer patient can generate up to 1 terabyte of biomedical data? Or that analysing wastewater can help&#8230;</p>
<p>The post <a href="https://bioalps.org/datarium-at-bioalps-networking-day/">Datarium at BioAlps Networking Day</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="768" height="477" src="https://bioalps.org/app/uploads/2026/11/Datarium-at-BND.png" class="attachment-large size-large wp-post-image" alt="Datarium at BND" style="float:left; margin:0 15px 15px 0;" decoding="async" srcset="https://bioalps.org/app/uploads/2026/11/Datarium-at-BND.png 768w, https://bioalps.org/app/uploads/2026/11/Datarium-at-BND-300x186.png 300w" sizes="(max-width: 768px) 100vw, 768px" />
<h3 class="wp-block-heading">Exploring the data of life during the BioAlps Networking Day with the Datarium exhibition created by the Swiss Institute of Bioinformatics. </h3>



<p class="wp-block-paragraph"><br><br>What if your future treatment were already written in your DNA? Did you know that a single cancer patient can generate up to 1 terabyte of biomedical data? Or that analysing wastewater can help predict epidemics? You can explore these questions and many more at Datarium, a Swiss Institute of Bioinformatics exhibition about how life-science data is changing our understanding of the world.</p>



<p class="wp-block-paragraph">The name combines <em>data</em> with the Latin suffix <em>-arium</em>, which means a place for hosting, keeping or exploring something. <a href="https://datarium.ch/">Datarium</a> takes visitors into the world of biological data: how varied it is, the expertise that makes sense of it, and its concrete impact on society. It shows how data can inform both personal choices and collective decisions.</p>



<p class="wp-block-paragraph">The exhibition is organised around five themes:</p>



<ul class="wp-block-list">
<li><a href="https://datarium.ch/sante-personnalisee/introduction">Personalised health</a></li>



<li><a href="https://datarium.ch/oncologie-de-precision/introduction">Precision oncology</a></li>



<li><a href="https://datarium.ch/lutte-contre-les-epidemies/introduction">Fighting epidemics</a></li>



<li><a href="https://datarium.ch/environnement/introduction">Protecting the environment</a></li>



<li><a href="https://datarium.ch/intelligence-artificielle/idees-recues">Artificial intelligence</a></li>
</ul>



<p class="wp-block-paragraph">Each theme shows how bioinformatics turns complex data into useful knowledge.</p>



<p class="wp-block-paragraph">Datarium was created in the context of the <a href="https://genevalovesdata.org/">#GenevaLovesData</a> initiative and is now travelling around Switzerland&#8221;.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f550.png" alt="🕐" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <strong>Free access</strong> all day at the BioAlps Networking Day<br><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f465.png" alt="👥" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <strong>Guided tours</strong> at 1 PM and 6 PM with <strong>Dorian Ziegler</strong> (SIB)<br><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> More information at the <strong>Swiss Institute of Bioinformatics</strong> booth during the event</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://bioalps.org/datarium-at-bioalps-networking-day/">Datarium at BioAlps Networking Day</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Neurosterix Announces $105 Million Series B Financing </title>
		<link>https://bioalps.org/neurosterix-announces-105-million-series-b-financing/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 07:38:32 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Funding]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[startup]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38332</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/10/Neurosterix-1024x636.png" class="attachment-large size-large wp-post-image" alt="Neurosterix" style="float:left; margin:0 15px 15px 0;" decoding="async" srcset="https://bioalps.org/app/uploads/2026/10/Neurosterix-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/10/Neurosterix-300x186.png 300w, https://bioalps.org/app/uploads/2026/10/Neurosterix-768x477.png 768w, https://bioalps.org/app/uploads/2026/10/Neurosterix-1536x954.png 1536w, https://bioalps.org/app/uploads/2026/10/Neurosterix-2048x1272.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" />Neurosterix, a Geneva-based clinical-stage biotechnology company developing novel, selective allosteric modulators for neuropsychiatric disorders, announced the closing of a $105 million Series B financing. The round was led by RTW Investments with participation from new investors Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, and Dellora Investments alongside existing investors Perceptive Advisors and Acorn&#8230;</p>
<p>The post <a href="https://bioalps.org/neurosterix-announces-105-million-series-b-financing/">Neurosterix Announces $105 Million Series B Financing </a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/10/Neurosterix-1024x636.png" class="attachment-large size-large wp-post-image" alt="Neurosterix" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/10/Neurosterix-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/10/Neurosterix-300x186.png 300w, https://bioalps.org/app/uploads/2026/10/Neurosterix-768x477.png 768w, https://bioalps.org/app/uploads/2026/10/Neurosterix-1536x954.png 1536w, https://bioalps.org/app/uploads/2026/10/Neurosterix-2048x1272.png 2048w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">Neurosterix, a Geneva-based clinical-stage biotechnology company developing novel, selective allosteric modulators for neuropsychiatric disorders, announced the closing of a $105 million Series B financing. The round was led by RTW Investments with participation from new investors Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, and Dellora Investments alongside existing investors Perceptive Advisors and Acorn Bioventures.</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>Proceeds will primarily support the planned advancement of Neurosterix’s lead clinical-stage program, NTX-253, a highly selective muscarinic M4 positive allosteric modulator (PAM), into Phase 2 clinical development for schizophrenia. The financing will also support the company’s broader pipeline of selective allosteric modulators for a range of neuropsychiatric disorders.</p>



<p class="wp-block-paragraph">In conjunction with the financing, Neurosterix announced three key leadership appointments: Andrew Miller, Ph.D., as Executive Chair of the Board of Directors; Edmund Harrigan, M.D., as an independent director; and, Stephen Brannan, M.D., as Chair of the Clinical Advisory Board. Each brings extensive experience in neuropsychiatric drug development, including senior leadership roles at Karuna Therapeutics, which pioneered a novel approach to treating schizophrenia through the development of COBENFY®, the first muscarinic-based therapy approved for the disease.</p>



<p class="wp-block-paragraph">“The clinical validation of muscarinic biology has created an important opportunity to develop the next generation of treatments for schizophrenia and other serious neuropsychiatric disorders,” said Fred Callori, Chief Executive Officer of Neurosterix. “We believe Neurosterix is entering a defining stage in its development with NTX-253, our selective M4 allosteric modulator, as we prepare to enter Phase 2 clinical development. With the support of an exceptional investor syndicate and the addition of Andrew, Ed and Steve, we now have the resources and expertise to advance our clinical programs and pursue our broader ambition of building a leading neuropsychiatric company.”</p>



<p class="wp-block-paragraph">“Muscarinic therapies have opened an important new chapter in the treatment of schizophrenia as the first ever non-dopamine-based treatments, which will bring multiple new treatment options for patients,” said Andrew Miller, Ph.D., Executive Chair of Neurosterix. “I believe Neurosterix’s highly selective approach to M4 modulation has the opportunity to be an important next generation muscarinic treatment building on promising early clinical findings and I look forward to working with the team to advance NTX-253 and help build Neurosterix into a leading company in neuropsychiatric therapeutics with a broader discovery platform capable of generating differentiated therapies.”</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>Advancing a differentiated approach to neuropsychiatric drug development</h3>



<p class="wp-block-paragraph">Neurosterix is developing highly selective allosteric modulators designed to regulate neural signaling pathways implicated in neuropsychiatric disorders. By fine-tuning receptor signaling rather than directly activating or blocking receptors, the company’s allosteric approach seeks to achieve more precise therapeutic effects with differentiated clinical profiles.</p>



<p class="wp-block-paragraph">The company’s lead program, NTX-253, is a highly selective, brain-penetrant M4 PAM targeting the muscarinic M4 receptor, a clinically validated target in schizophrenia. Neurosterix has completed Phase 1 single- and multiple-ascending-dose clinical studies of NTX-253; data demonstrated a pharmacokinetic profile supportive of once-daily oral dosing. These findings support further clinical evaluation of NTX-253 as a potentially differentiated antipsychotic treatment option.</p>



<p class="wp-block-paragraph">“The clinical validation of muscarinic biology represents an important advance in the treatment of schizophrenia, and we believe there is substantial opportunity for the next generation of therapies,” said Connor Williams, Senior Research Analyst at RTW Investments, LP who will join the Neurosterix Board of Directors. “Neurosterix combines a differentiated approach to receptor modulation with encouraging early clinical progress and a deep pipeline of novel programs. We are particularly excited by the opportunity to advance NTX-253 into Phase 2 development alongside a leadership team with an exceptional track record in neuropsychiatric drug development.”</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>Expanding a pipeline of differentiated neuropsychiatric therapies</h3>



<p class="wp-block-paragraph">Beyond NTX-253, Neurosterix is advancing novel allosteric modulators targeting additional pathways. NTX-819, a potentially first-in-class negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), supported by preclinical findings in models related to stress, mood and aggression. Neurosterix is also developing NTX-529, a second differentiated M4 PAM for potential applications in additional psychosis- and mood-related disorders.</p>



<p class="wp-block-paragraph">The company’s intellectual property portfolio includes more than 100 patent filings. Its discovery capabilities combine expertise in medicinal chemistry and receptor pharmacology with a proprietary library of more than 80,000 compounds and over 200 CNS-relevant functional assays to support the discovery and optimization of selective allosteric modulators addressing multiple therapeutic targets for high unmet medical needs.</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>Strengthening Neurosterix’s leadership with proven neuropsychiatric drug development expertise</h3>



<ul class="wp-block-list">
<li><strong>Andrew Miller, Ph.D.,</strong> is a highly accomplished biopharmaceutical executive with expertise in neuropsychiatric drug development, corporate strategy, and value creation. Most recently, he was the Founder and President of R&amp;D at Karuna Therapeutics, where he was the lead inventor of KarXT – now marketed by Bristol Myers Squibb as COBENFY® for the treatment of schizophrenia, the first novel mechanism approved in the indication in decades. He previously served as Karuna’s Chief Executive Officer, Chief Operating Officer, and as a member of its Board of Directors, guiding the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. Dr. Miller was named to <em>Time</em> magazine’s 100 Next Generation Leaders and 100 Most Influential People in Healthcare for 2025. Dr. Miller currently serves as Chairman of the Board of Progentos Therapeutics and a member of the Board of Alto Neuroscience, Kyverna Therapeutics, and Montara Therapeutics. He holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the University of Illinois at Urbana-Champaign.</li>



<li><strong>Edmund Harrigan, M.D.,</strong> is a board-certified neurologist with extensive pharmaceutical development and board leadership experience, including prominent leadership roles at Pfizer, where he served as the Senior Vice President and Worldwide Head of Regulatory Affairs and Safety, and Senior Vice President and Head of Worldwide Business Development, and as Vice President, Head of Neuroscience and Ophthalmology. Dr. Harrigan previously served on the boards of Karuna, Bellicum and PhaseBio and currently serves on the boards of Incyte, Acadia and Modulo Bio. He earned his B.A. degree in Chemistry from St. Anselm College, his M.D. from the University of Massachusetts, and trained in neurology at Boston University.</li>



<li><strong>Stephen Brannan, M.D.,</strong> previously served as Chief Medical Officer of Karuna where he led the development of COBENFY®. He has extensive experience leading successful clinical trials in psychiatry and neuroscience. Dr. Brannan previously held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, where he directed clinical development programs in schizophrenia, Alzheimer’s disease, and depression. His prominence in CNS clinical trials is reflected in his roles as a founding member of the CNS Summit Leadership Council and on the Scientific Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM). Dr. Brannan received his A.B. from Harvard University and his M.D. from the University of Texas Southwestern Medical School.</li>
</ul>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>About Neurosterix<br></h3>



<p class="wp-block-paragraph">Neurosterix is a clinical-stage biotechnology company based in Geneva-Switzerland, focused on transforming neuropsychiatric care through selective allosteric modulation. The company’s approach is designed to fine-tune brain signaling with greater precision and selectivity, with the goal of developing safer, more effective treatments for people living with schizophrenia, and mood and anxiety disorders. Neurosterix’s pipeline includes NTX-253, a selective muscarinic M4 positive allosteric modulator (PAM) for schizophrenia; NTX-819, a potentially first-in-class mGlu7 negative allosteric modulator (NAM) for mood and anxiety disorders; and NTX-529, a second differentiated M4 PAM for additional psychosis- and mood-related disorders. Neurosterix has operations in Boston and Geneva. </p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Source: <a href="https://www.businesswire.com/news/home/20261112398888/en/Neurosterix-Announces-%24105-Million-Series-B-Financing-and-Appointments-of-Leading-Neuropsychiatry-Drug-Development-Executives">Press Release</a> | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4f8.png" alt="📸" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ©Neurosterix</strong></p>
<p>The post <a href="https://bioalps.org/neurosterix-announces-105-million-series-b-financing/">Neurosterix Announces $105 Million Series B Financing </a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Game Changeuse</title>
		<link>https://bioalps.org/game-changeuse/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 10:02:16 +0000</pubDate>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[Life Sciences Events]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38324</guid>

					<description><![CDATA[<p><img width="768" height="477" src="https://bioalps.org/app/uploads/2025/04/Games-Changeuses.png" class="attachment-large size-large wp-post-image" alt="Game Changeuse" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2025/04/Games-Changeuses.png 768w, https://bioalps.org/app/uploads/2025/04/Games-Changeuses-300x186.png 300w" sizes="auto, (max-width: 768px) 100vw, 768px" />The Game Changeuse event is taking place on 25 February 2027 in Lausanne to discuss funding and leadership How can you identify the right sources of funding? How can you prepare to win over investors? How do you negotiate? How can you get to grips with your figures, assert your leadership and structure your strategy?When&#8230;</p>
<p>The post <a href="https://bioalps.org/game-changeuse/">Game Changeuse</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="768" height="477" src="https://bioalps.org/app/uploads/2025/04/Games-Changeuses.png" class="attachment-large size-large wp-post-image" alt="Game Changeuse" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2025/04/Games-Changeuses.png 768w, https://bioalps.org/app/uploads/2025/04/Games-Changeuses-300x186.png 300w" sizes="auto, (max-width: 768px) 100vw, 768px" />
<h3 class="wp-block-heading">The Game Changeuse event is taking place on 25 February 2027 in Lausanne to discuss funding and leadership</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>How can you identify the right sources of funding? How can you prepare to win over investors? How do you negotiate? How can you get to grips with your figures, assert your leadership and structure your strategy?<br>When faced with these challenges, women entrepreneurs do not always have the same opportunities.<br>To help reduce these inequalities, Les Game-Changeuses are back with a day of training, experience-sharing and networking, open to everyone! <br>On the programme: interactive workshops, targeted training sessions, testimonials from entrepreneurs, discussions with funding specialists and networking opportunities with the entrepreneurial ecosystem.<br>The aim: to move from theory to practice and leave with practical tools, new skills and greater confidence to tackle the next stages of your business’s development.</p>



<p class="wp-block-paragraph">Les Game-Changeuses 2027 is an event co-organised by GENILEM and the FIT – Foundation for Innovation and Technology, with the support of BCV, the CVCI Foundation and Retraites Populaires.<br></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4c5.png" alt="📅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> 25 February 2027 |<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Tibits, Lausanne | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f39f.png" alt="🎟" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Super Early Bird: CHF 75 until 15 November 2026 | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="https://formation.genilem.ch/formation/les-game-changeuses-2027/">Registration</a><br></strong></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://bioalps.org/game-changeuse/">Game Changeuse</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>European Academy of Neurology &#8211; Call for Abstract</title>
		<link>https://bioalps.org/european-academy-of-neurology-call-for-abstract/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 15:17:04 +0000</pubDate>
				<category><![CDATA[Opportunities]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38311</guid>

					<description><![CDATA[<p><img width="768" height="477" src="https://bioalps.org/app/uploads/2026/11/European-Academy-of-Neurology-V2.png" class="attachment-large size-large wp-post-image" alt="European Academy of Neurology - Call Abstract" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/European-Academy-of-Neurology-V2.png 768w, https://bioalps.org/app/uploads/2026/11/European-Academy-of-Neurology-V2-300x186.png 300w" sizes="auto, (max-width: 768px) 100vw, 768px" />Apply before 14 January 2027 for the European Academy of Neurology and get a chance to present your work at the event (12 &#8211; 15 June 2027 &#8211; Göteborg &#8211; Sweden) The EAN has long been known as Europe’s Home of Neurology, and this year the EAN Congress 2027 brings together the global neurology community&#8230;</p>
<p>The post <a href="https://bioalps.org/european-academy-of-neurology-call-for-abstract/">European Academy of Neurology &#8211; Call for Abstract</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="768" height="477" src="https://bioalps.org/app/uploads/2026/11/European-Academy-of-Neurology-V2.png" class="attachment-large size-large wp-post-image" alt="European Academy of Neurology - Call Abstract" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/European-Academy-of-Neurology-V2.png 768w, https://bioalps.org/app/uploads/2026/11/European-Academy-of-Neurology-V2-300x186.png 300w" sizes="auto, (max-width: 768px) 100vw, 768px" />
<h3 class="wp-block-heading">Apply before 14 January 2027 for the European Academy of Neurology and get a chance to present your work at the event (12 &#8211; 15 June 2027 &#8211; Göteborg &#8211; Sweden)</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>The EAN has long been known as Europe’s Home of Neurology, and this year the EAN Congress 2027 brings together the global neurology community in Gothenburg, Sweden, from 12–15 June, under the theme Transforming Neurology: Embracing Every Brain.&nbsp;<br>&nbsp;<br>The Congress is a unique opportunity for us to share our latest research, exchange scientific insights, and connect with colleagues from around the world!&nbsp;</p>



<p class="wp-block-paragraph">If you&#8217;re eager to present your groundbreaking research through an <a href="https://www.ean.org/congress2027/abstracts/oral-presentations" target="_blank" rel="noopener">oral</a> or <a href="https://www.ean.org/congress2027/abstracts/poster-presentations" target="_blank" rel="noopener">poster presentation</a> or <a href="https://www.ean.org/congress2027/abstracts/poster-display" target="_blank" rel="noopener">poster display</a>, this year&#8217;s event is the ideal opportunity to share your new discoveries, inspire new ideas and foster collaboration with our dedicated neurology community.&nbsp;</p>



<p class="wp-block-paragraph">Don&#8217;t miss out on this opportunity to be a part of something truly impactful!&nbsp;</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/23f0.png" alt="⏰" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Application deadline: 14 January 2027 (23:59 CET) | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Göteborg</strong> <strong>&#8211;</strong> <strong>Sweden</strong> |<strong> <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="https://www.ean.org/congress2027/abstracts/public-submission-instructions">Apply here</a></strong></p>
<p>The post <a href="https://bioalps.org/european-academy-of-neurology-call-for-abstract/">European Academy of Neurology &#8211; Call for Abstract</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Swiss Italian Startup Award</title>
		<link>https://bioalps.org/swiss-italian-startup-award/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 14:12:20 +0000</pubDate>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[Life Sciences Events]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38305</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-1024x636.png" class="attachment-large size-large wp-post-image" alt="Swiss Italian Startup Award" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />The Swiss Italian Startup Award is taking place on 24 November 2026 at Campus Biotech Geneva The&#160;Swiss&#160;Italian&#160;Startup&#160;Award&#160;returns to Campus Biotech for its 3rd edition, once again bringing together leading&#160;Italian&#160;entrepreneurs and investors in Geneva. Organised by the&#160;Italian&#160;Chamber of Commerce for Switzerland in partnership with several ecosystem partners, the event celebrates innovation, entrepreneurship and cross-border cooperation, strengthening&#8230;</p>
<p>The post <a href="https://bioalps.org/swiss-italian-startup-award/">Swiss Italian Startup Award</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-1024x636.png" class="attachment-large size-large wp-post-image" alt="Swiss Italian Startup Award" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/Swiss-Italian-Startup-Award.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">The Swiss Italian Startup Award is taking place on 24 November 2026 at Campus Biotech Geneva</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>The&nbsp;<a href="https://click.mailchimp.com/track/click/30010842/www.swissitalianstartupaward.ch?p=eyJzIjoidVRIQW5SekR0MG9rcGhPOHk0Zng4a3RZQm0wIiwidiI6MiwicCI6IntcInVcIjozMDAxMDg0MixcInZcIjoyLFwidXJsXCI6XCJodHRwczpcXFwvXFxcL3d3dy5zd2lzc2l0YWxpYW5zdGFydHVwYXdhcmQuY2hcXFwvXCIsXCJpZFwiOlwiODkzMWQzYjU1OTA5NDNjM2IwNmRlMmMyODgwOTExYjZcIixcInVybF9pZHNcIjpbXCI0YjgwMWY3NjdiMTM4OWU4NDlhOWFjMGY5M2YwZDhhYjA1MWIzZDAxXCJdLFwibXNnX3RzXCI6MTc5MzM2ODM0OH0ifQ" target="_blank" rel="noopener"><strong>Swiss&nbsp;Italian&nbsp;Startup&nbsp;Award</strong></a>&nbsp;returns to Campus Biotech for its 3rd edition, once again bringing together leading&nbsp;Italian&nbsp;entrepreneurs and investors in Geneva. Organised by the&nbsp;Italian&nbsp;Chamber of Commerce for Switzerland in partnership with several ecosystem partners, the event celebrates innovation, entrepreneurship and cross-border cooperation, strengthening the connections between the&nbsp;Swiss&nbsp;and&nbsp;Italian&nbsp;startup&nbsp;communities.</p>



<p class="wp-block-paragraph"><br>This year, the jury has selected <a href="https://click.mailchimp.com/track/click/30010842/www.swissitalianstartupaward.ch?p=eyJzIjoiUW4wYkIxZl84UDVra1VjY180UG1CdWpOSTd3IiwidiI6MiwicCI6IntcInVcIjozMDAxMDg0MixcInZcIjoyLFwidXJsXCI6XCJodHRwczpcXFwvXFxcL3d3dy5zd2lzc2l0YWxpYW5zdGFydHVwYXdhcmQuY2hcXFwvI2ZpbmFsaXN0c1wiLFwiaWRcIjpcIjg5MzFkM2I1NTkwOTQzYzNiMDZkZTJjMjg4MDkxMWI2XCIsXCJ1cmxfaWRzXCI6W1wiNGI4MDFmNzY3YjEzODllODQ5YTlhYzBmOTNmMGQ4YWIwNTFiM2QwMVwiXSxcIm1zZ190c1wiOjE3OTMzNjgzNDh9In0" target="_blank" rel="noopener">12 promising startups</a> in AI and ICT, Advanced Engineering, Life Sciences and Longevity. You will see them pitch on stage to investors, corporate representatives and industry experts, then stay on for an evening of networking over apéro and music.</p>



<p class="wp-block-paragraph"><strong>What to expect:</strong></p>



<ul class="wp-block-list">
<li>An evening of engaging presentations and tech excellence</li>



<li>An award ceremony</li>



<li>A unique networking aperitif to engage with tech thought leaders, investors and industry experts.</li>
</ul>



<p class="wp-block-paragraph">Places are limited and registrations close on&nbsp;<strong>13 November</strong>, so we encourage you to secure your seat today.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f5d3.png" alt="🗓" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Tuesday, 24 November | 17:00–22:00 |<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /><a href="https://click.mailchimp.com/track/click/30010842/campusbiotech.ch?p=eyJzIjoiQlQzLWlEbU9fZ29MRWp3ZnJSMlcwU3AtWXNvIiwidiI6MiwicCI6IntcInVcIjozMDAxMDg0MixcInZcIjoyLFwidXJsXCI6XCJodHRwczpcXFwvXFxcL2NhbXB1c2Jpb3RlY2guY2hcXFwvXCIsXCJpZFwiOlwiODkzMWQzYjU1OTA5NDNjM2IwNmRlMmMyODgwOTExYjZcIixcInVybF9pZHNcIjpbXCIwOTkyYmFjY2U4MzRhNDA0YTM3YTMxNWZlOGRmYTg1NDkwZWMxMTExXCJdLFwibXNnX3RzXCI6MTc5MzM2ODM0OH0ifQ" target="_blank" rel="noopener">Campus Biotech</a>, <a href="https://www.google.com/maps/search/Chemin+des+Mines+9,+Geneva,+Switzerland?entry=gmail&amp;source=g">Chemin des Mines 9, Geneva, Switzerland</a> | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="https://www.swissitalianstartupaward.ch/">More Information</a><br></strong></p>
<p>The post <a href="https://bioalps.org/swiss-italian-startup-award/">Swiss Italian Startup Award</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Bewe Lab Gets Support from Lichtsteiner Foundation</title>
		<link>https://bioalps.org/bewe-lab-gets-support-from-lichtsteiner-foundation/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 11:38:16 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Digital Health]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[start-up]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38298</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-1024x636.png" class="attachment-large size-large wp-post-image" alt="Bewe Lab Team 2026" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />Changing eating and drinking habits doesn’t have to start with restriction. Bewe Lab, a spinoff of the University of Fribourg (UNIFR) based in Biopôle Epalinges, is taking a different approach to a complex and often overlooked challenge: understanding and managing compulsive behaviours. The start-up just secured support from Lichtsteiner foundation. Measuring cravings through play Bewe&#8230;</p>
<p>The post <a href="https://bioalps.org/bewe-lab-gets-support-from-lichtsteiner-foundation/">Bewe Lab Gets Support from Lichtsteiner Foundation</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-1024x636.png" class="attachment-large size-large wp-post-image" alt="Bewe Lab Team 2026" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/Bewe-Lab-Team-2026.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">Changing eating and drinking habits doesn’t have to start with restriction. Bewe Lab, a spinoff of the University of Fribourg (UNIFR) based in Biopôle Epalinges, is taking a different approach to a complex and often overlooked challenge: understanding and managing compulsive behaviours. The start-up just secured support from Lichtsteiner foundation. </h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>Measuring cravings through play</h3>



<p class="wp-block-paragraph"><a href="https://www.bewe.com/">Bewe Lab</a> has developed a gamified mobile app that estimates cravings, such as those linked to obesity or addiction, by analysing users’ reaction times. These subtle behavioural signals show how intense compulsive urges are and how they change over time. Users need only a few minutes of interaction a day.</p>



<p class="wp-block-paragraph">Built on years of research in neuroscience, the solution turns behavioural science into an accessible digital experience that could make healthier choices easier and more lasting.</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>From data to clinical impact</h3>



<p class="wp-block-paragraph">Bewe Lab is working with the Swiss Data Science Center (SDSC) to refine its data analysis models and make its predictions more accurate and clinically relevant. The project brings together hospitals, health insurers and medtech companies, part of a broader shift toward integrated, data-driven care pathways. The goal is to enable earlier intervention and more personalised support for patients, using tools that are both accessible and scalable.</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>About the Lichtsteiner Foundation </h3>



<p class="wp-block-paragraph">The <a href="https://lichtsteinerfoundation.org/">Lichtsteiner Foundation</a> supports early stage start-ups (in Medtech, Life Science, Mental Health, Public Health and Wellbeing), to help pioneers bring their inventions to life. The Foundation focuses on impact investing by providing funding in the form of equity.</p>



<p class="wp-block-paragraph"><br><br></p>



<p class="wp-block-paragraph"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Source: <a href="https://lnkd.in/p/eETngCb6">Liechsteiner Foundation</a> | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4f8.png" alt="📸" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ©BeweLab, BeweLab&#8217;s Team<br></strong><br></p>
<p>The post <a href="https://bioalps.org/bewe-lab-gets-support-from-lichtsteiner-foundation/">Bewe Lab Gets Support from Lichtsteiner Foundation</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Swiss Biotech Association appoints Nicolas Durand as CEO and Odile Rundquist as Chief Strategy &#038; Growth Officer</title>
		<link>https://bioalps.org/swiss-biotech-association-appoints-nicolas-durand-as-ceo-and-odile-rundquist-as-chief-strategy-growth-officer/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 11:21:26 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Biotech]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38294</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-1024x636.png" class="attachment-large size-large wp-post-image" alt="SBA - Nomination - V2" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />The Swiss Biotech Association has appointed Nicolas Durand as CEO, effective 1 January 2027, and Odile Rundquist as Chief Strategy &#38; Growth Officer, as of 1 December 2026. Nicolas Durand will assume overall executive responsibility for the association, while Odile Rundquist will focus on strategic development, partnerships, and access to capital. The association’s priorities remain unchanged: supporting its members and strengthening&#8230;</p>
<p>The post <a href="https://bioalps.org/swiss-biotech-association-appoints-nicolas-durand-as-ceo-and-odile-rundquist-as-chief-strategy-growth-officer/">Swiss Biotech Association appoints Nicolas Durand as CEO and Odile Rundquist as Chief Strategy &amp; Growth Officer</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-1024x636.png" class="attachment-large size-large wp-post-image" alt="SBA - Nomination - V2" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/SBA-Nomination-V2.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">The Swiss Biotech Association has appointed Nicolas Durand as CEO, effective 1 January 2027, and Odile Rundquist as Chief Strategy &amp; Growth Officer, as of 1 December 2026. Nicolas Durand will assume overall executive responsibility for the association, while Odile Rundquist will focus on strategic development, partnerships, and access to capital. The association’s priorities remain unchanged: supporting its members and strengthening the Swiss biotech industry.</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>Nicolas Durand brings experience in biotechnology entrepreneurship, fundraising, and industry representation. He is CEO of Fondation Campus Biotech Geneva and Vice President of economiesuisse. He founded Abionic in 2010 and led the company until 2024, raising approximately CHF 120 million. As CEO, he will oversee the association’s operations, finances, its external representation, and the implementation of the strategy approved by the board.</p>



<p class="wp-block-paragraph">Odile Rundquist is a partner at Bioqube Ventures and has more than 20 years of experience in life sciences, investment and corporate governance. Her background includes pharmaceutical equity research, family office advisory and venture capital. Reporting to the CEO, she will advance strategic growth initiatives, strengthen engagement with investors and pharmaceutical partners, and enhance the&nbsp;association’s international positioning to create value for members.</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>Continuity and a smooth leadership transition</h3>



<p class="wp-block-paragraph">«We are pleased to welcome Nicolas and Odile to the&nbsp;Swiss&nbsp;BiotechAssociation. As a founder and&nbsp;biotech&nbsp;CEO, Nicolas brings entrepreneurial experience and credibility to lead the&nbsp;association. Odile is well positioned to strengthen our relations with investors and pharmaceutical partners. Together, they will build on the strong foundation established by Michael Altorfer and his team», says Patrick Amstutz, President of the&nbsp;Swiss&nbsp;Biotech&nbsp;Association. «On behalf of the&nbsp;Swiss&nbsp;biotech&nbsp;industry, I thank Michael for his leadership over the past decade. He has established the&nbsp;association&nbsp;as a central resource for our industry and helped positioning Switzerland as a leading international&nbsp;biotechhub. Michael is working closely with Nicolas and Odile to ensure a smooth transition. Our priorities remain unchanged: creating value for members, facilitating access to talent, technology, and capital, fostering favorable conditions and industry platforms, such as the&nbsp;Swiss&nbsp;Biotech&nbsp;Day, one of the ecosystem’s leading global events.»</p>



<p class="wp-block-paragraph">Incoming CEO Nicolas Durand said: «I am honored to have been entrusted with leading the&nbsp;Swiss&nbsp;Biotech&nbsp;Association&nbsp;and building on the work of Michael Altorfer, the board, and the team. I am looking forward to an open dialogue with our members, strengthening the practical value the&nbsp;association&nbsp;provides and ensuring that the voice of&nbsp;Swiss&nbsp;biotech&nbsp;is heard in political and economic debates. I look forward to shaping the&nbsp;association’s next chapter.»</p>



<p class="wp-block-paragraph">Odile Rundquist added: «Switzerland has an exceptional&nbsp;biotech&nbsp;ecosystem, with world-class science, entrepreneurial talent and a strong pharmaceutical industry. The&nbsp;Swiss&nbsp;Biotech&nbsp;Association&nbsp;can play an increasingly important role in connecting these strengths, helping entrepreneurs navigate the ecosystem and facilitating access to the right partners and capital at every stage of their development. I look forward to working with Nicolas, the board and the team, to create even greater value for our members.»</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Source: Swiss Biotech Association Press Release | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4f8.png" alt="📸" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Nicolas Durand, CEO of Swiss Biotech Association (effective 1 January 2027, and Odile Rundquist, Chief Strategy &amp; Growth Officer, as of 1 December 2026). </strong></p>
<p>The post <a href="https://bioalps.org/swiss-biotech-association-appoints-nicolas-durand-as-ceo-and-odile-rundquist-as-chief-strategy-growth-officer/">Swiss Biotech Association appoints Nicolas Durand as CEO and Odile Rundquist as Chief Strategy &amp; Growth Officer</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ExcellGene celebrates 25 years of biotechnology innovation</title>
		<link>https://bioalps.org/excellgene-celebrates-25-years-of-biotechnology-innovation/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Thu, 05 Nov 2026 15:58:47 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Health Valley]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38278</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-1024x636.png" class="attachment-large size-large wp-post-image" alt="ExcellGene 25 years" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years.png 1439w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />Based in Monthey (VS) since 2003, ExcellGene last week celebrated 25 years of biotechnology innovation also marking the leadership transition from Maria J. Wurm, former Chief Executive Officer, to its new CEO, Luca Valeggia. Founded in 2001, ExcellGene was the first biotechnology company in Valais, a spark that gave rise to the entire local biotech&#8230;</p>
<p>The post <a href="https://bioalps.org/excellgene-celebrates-25-years-of-biotechnology-innovation/">ExcellGene celebrates 25 years of biotechnology innovation</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-1024x636.png" class="attachment-large size-large wp-post-image" alt="ExcellGene 25 years" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/ExcellGene-25-years.png 1439w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">Based in Monthey (VS) since 2003, ExcellGene last week celebrated 25 years of biotechnology innovation also marking the leadership transition from Maria J. Wurm, former Chief Executive Officer, to its new CEO, Luca Valeggia.</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Founded in 2001, ExcellGene was the first biotechnology company in Valais, a spark that gave rise to the entire local biotech ecosystem, which now includes BioArk, the BioAlps network and others.</p>



<p class="wp-block-paragraph">Spun out of the EPFL lab of Florian M. Wurm, ExcellGene owes its scientific legacy to several groundbreaking technologies. The TubeSpin® bioreactor technology, now used by hundreds of laboratories worldwide, was invented by Dr. Maria J. Wurm while still a Senior Scientist at EPFL. Professor Florian Wurm and co-workers pioneered transposon-based gene transfer in Chinese Hamster Ovary (CHO) cells, another disruptive impact for the industry. At ExcellGene, TubeSpin®, JumpExpress® transposon technology and CHOExpress® cells support young and more established pharma clients from research through manufacturing: Rapid transient expression to accelerate research, and the comprehensive generation of highly productive, stable cell lines ready for commercial-scale production of innovative therapeutic agents.</p>



<p class="wp-block-paragraph">With more than 600 manufacturing cell lines created and over 50 clinical programs supported, the scientific and technical teams at ExcellGene have proven that therapeutic proteins and vaccine antigens made using CHO- and HEK-based manufacturing processes can be delivered very fast through ExcellGene&#8217;s science-driven approach.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph"><em>&#8220;We were here in Valais when pharmaceutical biotechnology was barely a known term, and seeing ExcellGene give rise to an industrial community with hundreds of jobs in and around the BioArk ecosystem is something we are very proud of.&#8221; &#8211;</em> <strong><em>Maria and Florian Wurm, co-founders of ExcellGene</em></strong></p>
</blockquote>



<p class="wp-block-paragraph">Luca Valeggia, ExcellGene&#8217;s new CEO, is now tasked with carrying this vision forward: strengthening the company&#8217;s global commercial presence, while integrating new technologies to accelerate cell line development and optimize production. A balance between innovation and operational excellence that will guide the company and its soon-to-be 70 employees.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph"><em>&#8220;Our ambition is to build on ExcellGene’s scientific excellence, expand our global reach and help customers bring innovative biologics closer to patients. I look forward to shaping this journey together with our team and partners.&#8221; &#8211;</em> <strong><em>Luca Valeggia, CEO of ExcellGene</em></strong></p>
</blockquote>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Source: <a href="https://excellgene.com/posts/excellgene-celebrates-25-years-a-pioneer-of-valais-biotech-looks-to-the-future?utm_campaign=25th%20Anniversary&amp;utm_medium=%5BLinkedIn%5D%20ExcellGene%20SA%20%5B2%5D&amp;utm_source=Twenty-five%20years%20ag...%20%28Social%20Post%20created%20on%202026-11-05%29">Press Release</a> | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4f8.png" alt="📸" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ©ExcellGene, ExcellGene&#8217;s Team</strong></p>
<p>The post <a href="https://bioalps.org/excellgene-celebrates-25-years-of-biotechnology-innovation/">ExcellGene celebrates 25 years of biotechnology innovation</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>HUG to Lead a Major Trial Testing Cell Therapy for Advanced Heart Failure</title>
		<link>https://bioalps.org/hug-to-lead-a-major-trial-testing-cell-therapy-for-advanced-heart-failure/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Thu, 05 Nov 2026 15:51:20 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Deeptech]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38268</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-1024x636.jpg" class="attachment-large size-large wp-post-image" alt="HUG - Dr Juan F. Iglesias" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-1024x636.jpg 1024w, https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-300x186.jpg 300w, https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-768x477.jpg 768w, https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias.jpg 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />Geneva University Hospitals (HUG) has received over CHF 1 million from the Swiss National Science Foundation to take part in RenuHEART, an international phase III trial that uses patients’ own bone marrow cells to treat heart failure. Heart failure affects more than 26 million people worldwide, including over 100,000 in Switzerland. Patients whose disease is&#8230;</p>
<p>The post <a href="https://bioalps.org/hug-to-lead-a-major-trial-testing-cell-therapy-for-advanced-heart-failure/">HUG to Lead a Major Trial Testing Cell Therapy for Advanced Heart Failure</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-1024x636.jpg" class="attachment-large size-large wp-post-image" alt="HUG - Dr Juan F. Iglesias" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-1024x636.jpg 1024w, https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-300x186.jpg 300w, https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias-768x477.jpg 768w, https://bioalps.org/app/uploads/2026/11/HUG-Dr-Juan-F.-Iglesias.jpg 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">Geneva University Hospitals (HUG) has received over CHF 1 million from the Swiss National Science Foundation to take part in RenuHEART, an international phase III trial that uses patients’ own bone marrow cells to treat heart failure.</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><br>Heart failure affects more than 26 million people worldwide, including over 100,000 in Switzerland. Patients whose disease is advanced and who still have symptoms despite treatment have very few options left.</p>



<p class="wp-block-paragraph">RenuHEART aims to give them one. Doctors collect bone marrow cells from the patient, stimulate them, and inject them back directly into the coronary arteries that supply the heart muscle. UK teams have been developing this approach for about ten years, and earlier trials have shown encouraging results. The phase III trial will test whether it is safe and effective in a larger group of patients, looking at prognosis, heart function and quality of life.</p>



<p class="wp-block-paragraph">The project is funded through a joint call by the Swiss National Science Foundation (SNSF) and the UK’s National Institute for Health and Care Research (NIHR). Total funding exceeds CHF 6 million, of which CHF 1,045,803 goes to the HUG. Prof. Anthony Mathur of Barts Heart Centre in London leads the study overall. Dr Juan F. Iglesias of the HUG Cardiology Department is the Swiss principal investigator.</p>



<p class="wp-block-paragraph">Several Swiss cardiology departments are taking part. All Swiss patients assigned to receive the therapy will be treated at the HUG. The trial is open to adults with advanced heart failure who remain symptomatic despite available treatments and have no other therapeutic option.</p>



<p class="wp-block-paragraph">“This study marks an important step in evaluating a new therapeutic approach,” says Dr Iglesias.</p>



<p class="wp-block-paragraph">The HUG team also includes Prof. Philippe Meyer (Cardiology), Prof. Jean Villard (cell therapy and transplantation laboratory), Prof. Yves Chalandon (Haematology) and Dr Dulce Alfaiate (HUG-UNIGE Clinical Research Centre).</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><br><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Source: <a href="https://www.hug.ch/actualite/recherche-therapie-cellulaire-innovante-pour-traiter-insuffisance-cardiaque">HUG</a> | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4f8.png" alt="📸" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ©Dr Juan F. Iglesias, HUG</strong></p>
<p>The post <a href="https://bioalps.org/hug-to-lead-a-major-trial-testing-cell-therapy-for-advanced-heart-failure/">HUG to Lead a Major Trial Testing Cell Therapy for Advanced Heart Failure</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Twice as many Swiss now ask AI about their symptoms</title>
		<link>https://bioalps.org/twice-as-many-swiss-now-ask-ai-about-their-symptoms/</link>
		
		<dc:creator><![CDATA[Sandra Ansanay-Alex]]></dc:creator>
		<pubDate>Thu, 05 Nov 2026 15:47:42 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://bioalps.org/?p=38271</guid>

					<description><![CDATA[<p><img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-1024x636.png" class="attachment-large size-large wp-post-image" alt="CSS Study - IA Health" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />The 2026 CSS Health Study shows chatbots are fast becoming part of how people in Switzerland manage their health, from checking symptoms to coping with loneliness. Not feeling well? More and more people in Switzerland now ask a chatbot before they call a doctor. According to the 2026 CSS Health Study, 42% of respondents have&#8230;</p>
<p>The post <a href="https://bioalps.org/twice-as-many-swiss-now-ask-ai-about-their-symptoms/">Twice as many Swiss now ask AI about their symptoms</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></description>
										<content:encoded><![CDATA[<img width="1024" height="636" src="https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-1024x636.png" class="attachment-large size-large wp-post-image" alt="CSS Study - IA Health" style="float:left; margin:0 15px 15px 0;" decoding="async" loading="lazy" srcset="https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-1024x636.png 1024w, https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-300x186.png 300w, https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health-768x477.png 768w, https://bioalps.org/app/uploads/2026/11/CSS-Study-IA-Health.png 1440w" sizes="auto, (max-width: 1024px) 100vw, 1024px" />
<h3 class="wp-block-heading">The 2026 CSS Health Study shows chatbots are fast becoming part of how people in Switzerland manage their health, from checking symptoms to coping with loneliness.</h3>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>Not feeling well? More and more people in Switzerland now ask a chatbot before they call a doctor. According to the 2026 CSS Health Study, 42% of respondents have used an AI chatbot to interpret their symptoms. That’s double last year’s 20%.</p>



<p class="wp-block-paragraph">The study was carried out by the Sotomo research institute for the health insurer CSS, surveying 2,459 people across Switzerland’s language regions. It shows the trend reaching every age group. Among young adults, 62% have used AI to check symptoms. Among people over 65, the share tripled, from 10% to 30%.</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>A supplement, not a substitute</h3>



<p class="wp-block-paragraph">Chatbots aren’t replacing doctors yet. Doctors, internet searches and friends and family are still people’s main sources of health information. But AI is catching up: 28% now name chatbots as a key source for physical symptoms (up from 18%), and 16% for psychological ones (up from 11%). The study also points to a more personal role. Among isolated people who use AI for personal matters, 27% say it made them feel less alone. Almost one in five personal AI users have told a chatbot something they’ve never told anyone else. Meanwhile, only 50% now turn to relatives when they are in psychological distress, the lowest share since 2022.</p>



<p class="wp-block-paragraph"></p>



<h3 class="wp-block-heading"><br><br>Is digital harming health?</h3>



<p class="wp-block-paragraph">Young people are the most critical of digital technology. 44% of 18–35-year-olds think their use of digital media harms their long-term health, compared with just 8% of over-65s. Overall, people feel healthier this year: 66% rate their health as good or very good, up from 62%. Diet is gaining ground as a perceived driver of serious disease, now tied with genetics at 59%. Even so, only 22% say they eat five portions of fruit and vegetables a day. And 76% support mandatory labels showing how processed a food is.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br>For digital health innovators, the message is clear. Patients are already using AI, and they’re doing it on their own. The opportunity now is to build tools that are reliable, safe and connected to professional care.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><br><br><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/27a1.png" alt="➡" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Source: <a href="https://www.css.ch/fr/a-propos-de-css/portrait/medias-publications/medias/communiques-de-presse/css-etude-sante-2026.html">CSS Health Study 2026</a> | <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4f8.png" alt="📸" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ©</p>
<p>The post <a href="https://bioalps.org/twice-as-many-swiss-now-ask-ai-about-their-symptoms/">Twice as many Swiss now ask AI about their symptoms</a> appeared first on <a href="https://bioalps.org">BioAlps</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
